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Abstract: The present review focuses on preclinical and clinical studies conducted in the last decade
that contribute to increasing knowledge on Coenzyme Q10’s role in health and disease. Classical
antioxidant and bioenergetic functions of the coenzyme have been taken into consideration, as well
as novel mechanisms of action involving the redox-regulated activation of molecular pathways
associated with anti-inflammatory activities. Cardiovascular research and fertility remain major
fields of application of Coenzyme Q10, although novel applications, in particular in relation to topical
application, are gaining considerable interest. In this respect, bioavailability represents a major
challenge and the innovation in formulation aspects is gaining critical importance.
Keywords: Coenzyme Q; ubiquinol; cardiovascular disease; reproductive medicine; skeletal muscle
health; skin health; neurodegeneration; ophthalmology
1. Introduction
Coenzyme Q10 (CoQ), is an endogenous lipophilic quinone, ubiquitous in biological mem-
branes, where it acts as a cofactor of mitochondrial respiratory complexes supporting cellular
bioenergetics. Its reduced form (ubiquinol) is endowed with antioxidant activities both as a
radical scavenger and also supporting, synergistically, the larger cellular antioxidant network.
These two functions, bioenergetic and antioxidant, characterized Coenzyme Q research in the
last half of the 21st century, while in the first decades of the new millennium, research has
unleashed novel functions of CoQ, highlighting its role in modulating gene expression, mito-
chondrial function and signaling, with important implications in the senescence process and
cell death. These biochemical aspects have been investigated in clinical studies, highlighting
the critical role of CoQ in health and disease. The present review focuses on novel research
and the clinical findings of the past 10 years and represent an update on our previous reports,
published between 2007 [1] and 2010 [2], that have already laid an important foundation in
terms of discussing literature related to the clinical aspects and biological properties of CoQ in
ameliorating different disease conditions.
PubMed, EMBASE, and Google Scholar databases/search engines were used to iden-
tify eligible studies. Included studies had to report on the health effect of CoQ as well as
being listed among keywords ubiquinone, ubiquinol, CoQ, and ubidecarenone, and should
have been published between 2010 and 2021. A total of 450 articles met the inclusion
criteria, and among these, 333 referred to original research articles and 117 were reviews.
The most prominent topic was cardiovascular health (21%), fertility (12%) and skeletal
muscle health (7%), the latter comprising clinical aspects and physical exercise aspects
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within physiological conditions and sport nutrition. Bioavailability studies comparing
formulations have attracted significant attention (8%), probably driven by a major uprise
in the number of ubiquinol formulas claiming enhanced bioavailability as well as other
formulas. Altogether, these studies highlight a major limitation of CoQ application in
human studies associated with its low bioavailability, in particular to specific tissues, such
as the skeletal and cardiac muscle and, consequently, the efforts in improving delivery
strategies. Partially associated with this topic, novel aspects receiving increasing interest in
the literature, refer to the topical application of CoQ to skin (2%) and ophthalmology (2%).
2. Cardiovascular Health
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, ac-
counting for approximately 32% of all global deaths that occurred in 2019 [3]. Aging
represents the main risk factor being consistently linked with pathological modifications
such as systemic low-grade inflammation, increased arterial stiffness and endothelial dys-
function, processes that may lead to elevated blood pressure (BP) as well as reduced or
diminished left ventricular (LV) function [4]. The latter remains the major characteristic
feature of diverse cardiovascular pathologies, such as cardiomyopathies, that may lead
to heart failure [5]. Moreover, modifiable risk factors involving lifestyle choices, such as
tobacco smoking, harmful use of alcohol, and obesity, which may be induced by physi-
cal inactivity and overnutrition, are acknowledged to also play an important role in the
pathogenesis of several CVDs. In particular, in the last decade, several reviews, both
with a comprehensive or systematic approach, have been published, related to CoQ and
its impact on CVD-related complications. For instance, in 2012, Krim and colleagues [6]
indicated the gap in evidence that could confirm the benefits of micronutrients, including
CoQ, in patients with chronic heart failure. However, a pooled analysis of published
literature in 2012, by Gao and colleagues [7] showed that CoQ supplementation could
improve endothelial function assessed peripherally by flow-mediated dilation in patients
with and without established CVDs. Similarly, a meta-analysis conducted by Fotino and
co-workers [8], published in the following year (2013), revealed that CoQ supplementa-
tion may improve the ejection fraction in patients with congestive heart failure. In 2014,
Kosmas and colleagues [9] affirmed that additional clinical trials are required to definitely
determine the effect of statins on chronic congestive heart failure, including how the endoge-
nous levels of CoQ are impacted. In contrast, different review papers published between
2015–2016 [10–14] validated claims that CoQ supplementation can significantly reduce
morbidity and mortality in patients with heart failure or cardiovascular events; however,
these articles also cautioned on the limitation of clinical studies informing on these positive
outcomes. Recent reviewed evidence from our group [15,16] and others, including Suárez-
Rivero and co-workers [17], as well as Dragan and colleagues [18], have explored the
literature on the diverse therapeutic mechanisms that could be attributed to the beneficial
effects of CoQ against CVD-related complications. These mainly involve its strong antioxi-
dant and anti-inflammatory properties, especially the reduced form of CoQ (ubiquinol),
which also appears to be less studied in comparison to its oxidized counterpart. These
limitations highlight the advantages of the current review, where not just information on
the impact of CoQ on CVD-related outcomes is updated, but also implications of dose are
discussed. More details on the mechanism of action of CoQ have been provided by preclini-
cal studies using different preclinical experiments using cultured cells or animal models. In
HUVECs or H9c2 exposed to elevated concentrations of palmitate or high glucose, to mimic
the detrimental effects that metabolic stress has on cardiac physiology, CoQ deficiency
has been consistent with the development of oxidative stress [19–21]. Precisely, these
studies show that CoQ deficiency in such conditions promotes increased ROS generation,
and depletion of intracellular antioxidant defense systems, such as uncoupling protein 2
(UCP2), and superoxide dismutase 2 (SOD2), leading to cellular damage. Apparently, in
HUVECs subjected to conditions of oxidative stress and inflammation, using stressors such
as oxidized low-density lipoprotein (oxLDL) or lipopolysaccharide (LPS), CoQ treatment
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proves to be effective in suppressing endothelial oxidative injuries [22–25]. Here, prime
mechanisms of protection against oxidative stress include blocking the activities of protein
kinase C (PKC)/NADPH oxidase, as well as improving mitochondrial function. In relation
to inflammation, Olivieri and colleagues [23] demonstrated that the reduced form of CoQ
(ubiquinol) could attenuate LPS-induced microRNA (miR)-146a and interleukin-1 receptor
(IL-1R) associated kinase (IRAK-1) modulation but failed to curb interleukin (IL)-6 release.
This result is of interest, since emerging clinical data already suggest that CoQ intake
can significantly affect the expression of more than 100 different microRNAs related to
the development of CVDs [26]. On the other hand, using in vivo models, low plasma
levels of CoQ in rats with cardiovascular diseases (congenital and acquired) [27,28] with
spontaneous myxomatous mitral valve degeneration (MMVD) has been associated with
increased levels of lipid peroxidation and the enhanced severity of congestive heart failure.
Indeed, Gvozdjáková and colleagues [29] demonstrated that raised levels of CoQ in plasma
and myocardial tissue were linked with reduced malondialdehyde (MDA) (a marker of
lipid peroxidation) and improved activity of the mitochondrial electron transport chain.
These data suggest that strategies to enhance plasma or cardiac tissue levels of CoQ could
prove essential to ameliorate CVD-related complications. Furthermore, several studies
have reported on the impact of CoQ in reverting ischemia-reperfusion injury or hyper-
tension in animal models. Presented evidence showed that CoQ administration could
block lipid peroxidation products and expressions of inducible/endothelial nitric oxide
synthase, and apoptosis [30–33]. From the current results, it could be hypothesized that
therapeutic mechanisms of action for CoQ involves improving endothelial function, in
part by enhancing nitric oxide bioavailability in addition to blocking oxidative stress and
inflammation. This was, in fact, verified by Kozaeva and colleagues [34], showing that
CoQ supplementation improved nitric oxide-mediated vasodilation in Wistar rat aortas.
Moreover, Kulyak and co-workers showed that CoQ treatment could protect against the
development of myocardial hypertrophy in an experimental model of coronary artery oc-
clusion [35]. Overall, the results from other studies demonstrate that CoQ supplementation
could effectively attenuate oxidative stress and inflammation to reduce cardiac remod-
eling or hinder doxorubicin-induced cardiotoxicity [36,37]. This is in line with studies
showing that CoQ supplementation in rats could lower the levels of triglycerides and total
cholesterol in apoprotein E deficient mice [38,39]. These findings suggest that, besides
directly inhibiting lipid peroxidation products, CoQ can lower plasma cholesterol, thus
indirectly preventing its reaction with radicals, and in the process block the development
of atherosclerosis and related complications. It is noteworthy that CoQ also appears to
play a major role in improving cardiac mitochondrial function in experimental models of
CVD [40,41]. This aspect is essential, since mitochondria are known to play an important
role in energy generation and calcium homeostasis [42], which are vital processes for an
efficient cardiac physiology. Finally, Table 1 summarizes clinical evidence on the impact
of CoQ supplementation on human cardiovascular status both in healthy and in CVD
subjects. Concerning pathological patients, Q-SYMBIO represents one of the most impor-
tant multinational prospective, randomized, double-blind trials performed to evaluate the
role of ubiquinol supplementation (100 mg, 3 times daily for 2 years) in 420 patients with
moderate to severe heart failure (HF). Although no significant differences were found in
primary short-term endpoints at 16 weeks (NYHA functional class, 6 min walk test, and
N-terminal pro–B-type natriuretic peptide), long-term endpoints were significantly lower
in the CoQ group compared with the placebo one, in particular in terms of cardiovascular
mortality (9% vs. 16%, p = 0.026), all-cause mortality (10% vs. 18%, p = 0.018), and incidence
of hospital stays for HF (p = 0.03) [43]. Moreover, since geographical differences in patient
characteristics and management can affect the outcomes in HF trials, Mortensen et al. [44]
assessed the consistency of the treatment effect of CoQ in the European sub-population of
231 patients, obtaining results that confirmed the efficacy of ubiquinol demonstrated
in the previous study. Similarly, in a double-blind study involving 102 HF patients,
Zhao et al. demonstrated that the use of 30 mg/day of CoQ for 12 months as adjuvant
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treatment was able to significantly attenuate the incidence of atrial fibrillation compared
to placebo group (6.3% vs. 22.2%, p = 0.02) [45]. The role of CoQ in the cardiovascular
health has also been demonstrated in subjects without CVD manifestations. Alehagen
et al. [46], in a 10-year prospective randomized, double-blind trial, evaluated cardiovas-
cular mortality in 443 healthy elderly Swedish subjects supplemented with 200 mg/day
of CoQ and 200 µg/day selenium or with placebo over a period of 4 years. In the treated
group, a reduced risk of cardiovascular mortality by 50% was observed not only during
the intervention period, but this persisted for the duration of the follow-up period. The
ability of CoQ to counteract CVD-related complications is mainly due to its bioenergetic
and antioxidant roles and its efficacy strictly depends on many factors, such as the dosage
and duration of supplementation. In 2012, Lee et al. [47] found significantly lower plasma
levels of CoQ in subjects with coronary artery disease (CAD) compared to the control group
(healthy individuals with normal blood biochemistry) and subjects with CoQ plasma levels
that are higher than 516 nmol/L showed a significantly lower risk of CAD. By supplement-
ing with 150 mg/day of CoQ for 8 weeks, the same authors showed a decrease in MDA
levels while, if the supplementation was extended to 12 weeks, a significant increase in
antioxidant enzyme activities (catalase and superoxide dismutase) in patients with CAD
occurred [48]. Finally, patients with CAD during statin therapy benefited from supple-
mentation with 300 mg/day of CoQ for 12 months in terms of both the enhancement of
antioxidant enzymes activities and lowering of inflammatory markers [49]. Although the
role of CoQ on counteracting the inflammatory response has been widely demonstrated,
in our recent study, supplementation with 400 mg/day of ubiquinol from 7 days before
to 5 days after aortic valve replacement in 50 elderly patients affected by severe aortic
stenosis, was not able to curb the inflammatory response triggered by cardiac surgery pro-
cedure [50]. This was probably due to a remarkably high inflammatory state (plasma IL-6
< 100 pg/mL) associated with the post-surgical intervention in this cohort, characterized
by elderly patients. In fact, studies supporting anti-inflammatory activity of CoQ in vivo
are associated with lower levels of inflammation [49,51,52]. Preclinical evidence on the
role of CoQ in improving endothelial functionality, previously reported, have also recently
been confirmed in clinical studies. Endothelial dysfunction is an early disease marker,
associated with different forms of CVD, such as hypertension, coronary artery disease,
chronic heart failure, peripheral artery disease, diabetes and chronic renal failure. This is
characterized by a reduced endothelial vasodilator response, mainly caused by a low NO
bioavailability and increased level of ROS [53]. Many studies highlighted the ability of
both ubiquinone and ubiquinol to counteract endothelial impairment in CVD patients. In a
randomized, double-blind, placebo-controlled trial, the supplementation with 300 mg/day
of CoQ for 8 weeks significantly improved endothelial function in 28 patients with ischemic
left ventricular systolic dysfunction compared to placebo [54]. Similarly, 14 patients with
chronic heart failure with reduced ejection fraction benefited from improved endothe-
lial functionality after supplementation with 400 mg/day of ubiquinol for 3 months [55].
In a study by Perez-Sanchez et al. [56] in addition to a decrease in pro-thrombotic and
pro-inflammatory mediators, an increase in mitochondrial size and an upregulation of
genes related to mitochondrial biogenesis, the authors also observed an enhancement
in endothelial function in 36 patients with antiphospholipid syndrome, supplemented
with 200 mg/day of ubiquinol for 1 month. In contrast, although there are few clinical
trials, there is no evidence supporting the ability of ubiquinone to improve endothelial
functionality in healthy subjects. Raitakari et al. [57] showed that 150 mg/day of CoQ for 4
weeks did not significantly increase the flow-mediated dilation (FMD) of the brachial artery
(4.3% vs. 5.1%, p = 0.99) in healthy hypercholesterolemic subjects. Conversely, our recent
study highlighted the protective effect of ubiquinol towards endothelial function in subjects
with mild-to-moderate dyslipidemia and with no other evidence of disease [58]. In this
randomized, double-blind study, 51 subjects with mild-to-moderate dyslipidemia and no
clinical signs of CVD were randomized to receive either ubiquinol (200 mg or 100 mg/day)
or placebo for 8 weeks. The baseline FMD values were found to be comparable to those
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observed in the Raitakari population study and, in both treated groups, a significant in-
crease in this parameter (200 mg/day = +1.28%; 100 mg/day = +1.34%) was observed. This
could be due to the significantly higher bioavailability of orally administrated ubiquinol,
compared with ubiquinone and its direct antioxidant activity [59].
3. Fertility
Infertility, defined as impossibility to conceive a child after more than one year of
unprotected sexual activity, is a common and emerging burden affecting 50 to 80 million
individuals [60]. Causes of infertility are heterogeneous and interest both male and female
partners. In this respect, in otherwise healthy subjects, in the absence of organic dysfunc-
tion, male infertility is often associated with altered number, motility and morphology of
spermatozoa (astenozoospermia); similarly female infertility is often related to the general
quality of oocytes [61]. Oxidative stress, often associated with metabolic dysfunction and
ageing, is a major factor influencing the qualitative parameters of gametes [62–64] and,
accordingly, the therapeutic use of antioxidants is a common strategy aiming to increase
the fertility rate [64]. Among antioxidant interventions, an important body of literature
already reviewed in Littarru et al., 2010 [2], supports the efficacy of CoQ both in improving
sperm quality in terms of count and motility, correlated to increasing Q10 levels in sper-
matozoa. This evidence was confirmed in recent studies showing that ubiquinone [65,66]
and ubiquinol [67,68] use in men affected by idiopathic oligoasthenozoospermia, led to
improved sperm count, motility and morphology, associated with an increase in spermatic
antioxidant defenses quantified as superoxide dismutase (SOD), catalase (CAT), glutathione
peroxidase (GPx) levels and sperm DNA integrity [65,66]. Moreover, Tirabassi et al. [69]
demonstrated that 3 months of 200 mg/day CoQ intervention, combined with 2.66 g/day
aspartic acid, on idiopathic asthenozoospermia patients, increased CoQ (p < 0.001) and
aspartic acid (p = 0.022) levels in sperm cells and seminal fluids, and were associated
with significant increases in SOD activity and a significant decrease in oxidative stress
markers (NO and DNA damage), the latter showing an inverse correlation with CoQ con-
tent. Overall, in this experimental setting, antioxidant protection was associated with an
increase in sperm motility (p < 0.001). Additionally, Safarinejad et al. [70], in an open label
prospective study, showed that CoQ supplementation (300 mg/day for one year), led to a
highly significant increase in sperm motility, density, and morphology, and was associated
with a 34% total pregnancy rate over 6 months. However, a strong limitation of this study
was the lack of a control group. Gvozdjáková et al. [71] reported the effect of ubiquinol in
association with other antioxidants (440 mg L-carnitine fumarate, 30 mg ubiquinol, 75 IU
vitamin E, 12 mg vitamin C) up to 6 months of treatment. They observed that an increase
in antioxidant content in seminal fluid was associated with a significant improvement in
spermatozoa kinetic parameters and a concomitant increase in 45% pregnancy rate. Finally,
Kobori et al. [72] reported that 6 months of treatment with CoQ (120 mg/day) and vitamin
E and C (80 and 40 mg < 7 day) led to a significant increase in sperm count and motility
as well as pregnancies (48 out of 169 patients) either natural or assisted with reproductive
technology. In relation to female fertility concerning oocyte quality, CoQ intervention was
considered in relation to poor ovarian reserve capacity, altered oxidative status, associated
with metabolic imbalances, and antioxidant deficiency in follicular fluids. Giannubilo
et al. [73] showed that ubiquinone oral supplementation (200 mg/day for 1 month) led to
an increase in follicular CoQ content, but antioxidant capacity measured through ORAC
assay was lower in CoQ-supplemented mature oocytes compared to untreated ones. This
counter-intuitive behavior of antioxidant capacity was interpreted by authors in light of
a dysfunctional blood-follicular barrier in mature subjects, leading to altered follicular
fluid composition and potential compensatory effects counteracted by CoQ, providing
a preservation of follicular homeostasis. Concerning in vitro fertilization technology, a
large retrospective study conducted by Gat et al. [74] on women with poor ovarian reserve
capacity and subjected to in vitro fertilization (IVF) or controlled ovarian hyperstimulation
plus intrauterine insemination (IUI), showed that the combined treatment of CoQ (600 mg
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per day) with dehydroepiandrosterone (DHEA), a steroid hormone (75 mg per day), was
superior in comparison with DHEA supplementation alone in increasing pre-stimulation
parameters in IVF and IUI cycles, such as follicular antral count (AFC) (p = 0.0001), mature
follicule number (p = 0.01) and gonadotropin dose (p = 0.003). Similarly, Xu et al. [75]
showed in a study involving 186 poor ovarian reserve capacity women supplemented with
CoQ before in vitro fertilization procedure, that there was a significant increase in high
quality embryos (p = 0.03), and estradiol production (p = 0.02). In this case, too, patients
required a lower gonadotropin induction dose. Finally, Bentov et al. [76] in a double-blind
placebo controlled randomized trial that included 27 in vitro fertilization-intra cytoplasmic
sperm injection (IVF-ICSI) patients, 35–43 years of age, taking either 600 mg of CoQ or
placebo, did not observe any differences in the post-meiotic aneuploidy rate; however, as
declared by the authors, the study was underpowered. Besides human studies, animal
models have provided additional evidence of the efficacy of CoQ and have led to some
important breakthroughs in terms of mechanistic interpretation of its beneficial effects.
In particular, in male Sprague Dawley rats exposed to a single dose of ionizing radia-
tion (10 gray), oral treatment with ubiquinone mg/kg for 2 weeks, was able to prevent
radiation-induced histological aberration and mitochondria pro-apoptotic signaling in
testes (p < 0.05), suggesting a role of CoQ in preventing mitochondria dysfunction and
its implication in testicular toxicity [77]. More evidence has been collected on models
of ovarian dysfunction using cyclophosphamide-treated rats, which showed that CoQ
intervention (22 mg/kg per day for 21 days) increased the number and quality of oocytes,
as well as embryo development stages, by modulating the expression of genes involved
in folliculogensis, such as proliferating cell nuclear antigen (PCNA) (p < 0.05) and folli-
cle stimulating hormone receptor (FSR) (p < 0.05) [78]. Oxidative stress, in particular in
females, is heavily involved with reproductive ageing, that notably has an early onset
compared to other vital functions. In this respect, Zhang et al. [79] showed the effect of CoQ
in improving post-ovulatory aged oocytes in mice, by suppressing markers of oxidative
damage while increasing the amount and physiological distribution of juno and ovastacin,
proteins with a critical function in the fertilization process, associated with sperm binding
activities. Similarly, Niu et al. [80] highlighted the promising effect of ubiquinol in rescu-
ing post-ovulatory aging in cultured porcine oocytes, through the induction of proteins
involved in mitochondrial biogenesis and mitophagy, such as SIRT1 and PGC1α at mRNA
level and Pink1 and Parkin 1 at the protein level. Regarding reproductive aging in animals,
Ben Meir et al. [81] reported that ubiquinone injected in mice at 22 mg/kg for a period of
least 12 weeks, was able to counteract oocyte aging in terms of ovarian reserve capacity
(p = 0.01) and oocyte quality (p = 0.05) in old mice. The novel efficacy mechanism of CoQ
was related to an improvement in mitochondrial oocyte functionality parameters, such as
active mitochondria pool (p < 0.001), flavin adenine dinucleotide (FAD) reduction capacity
(p < 0.001) and membrane potential (p < 0.05) in aged oocytes.
4. Muscle Health and Physical Exercise
The health benefits of moderate and regular physical exercise are well supported by
the scientific literature. On the other hand, strenuous physical exercise is associated with
detrimental effects due to an increase in oxygen consumption up to 100-fold higher than
under resting conditions in the skeletal muscle and a consequent rise in reactive oxygen
species (ROS) [82]. Previously, we reviewed several pieces of evidence supporting the
role of CoQ, related mainly to ubiquinone interventions, in improving aerobic capacity
in terms of maximal oxygen consumption and fatigue sensation. These outcomes are
mainly related to its capacity to attenuate oxidative stress and pro-inflammatory signaling,
to lowering levels of plasmatic markers of muscular damage (creatine kinase and myo-
globin) as well as to decreasing lipid peroxide exercise, induced in athletes [2]. In the last
decade, more evidence has also been gathered in relation to the use of the reduced form,
ubiquinol, which chemically is the active form as an antioxidant. Under physiological
conditions, both total CoQ content and its oxidative status, could be influenced, in par-
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ticular by aging, nutrition, drug use [83] and certainly by intense physical activity [84].
In relation to the latter, according to a study by Doring et al. [85], analyzing CoQ as a
determinant of muscular strength in two independent cohort studies on 1301 subjects,
the authors concluded that both low CoQ/cholesterol levels and the percentage of the
reduced form of CoQ, represent indicators of an increased risk of age-associated muscle
weakness and reduced muscle mass in humans due to their negative associations with
upper body muscle strength, peak flow and muscle mass. Sarcopenia, defined as a de-
crease in muscle quantity and quality [86], is a frequent disease condition associated with
aging, often characterized at the cellular level with structural and functional alterations
in skeletal muscle mitochondria. In this context, the association of mild regular physical
exercise and ubiquinol supplementation, as a mitochondrial nutrient, has been proposed
as a strategy to slow down skeletal muscle senescence and improve the quality of life in the
elderly. In this respect, in a murine model of accelerated ageing, SAMP8 mice [87] showed
that a 2 month program of physical exercise in this animal model significantly increased
mitochondrial muscle damage, but the combination with ubiquinol supplementation was
able to preserve mitochondrial ultrastructure, promoting mitochondrial biogenesis and
counteracting the deleterious effects of physical exercise-derived ROS in the senescence-
prone oxidative stress mouse model. Besides sarcopenia, the muscles of elderly people are
at higher risk of developing myopathy as a side effect of statin treatment [88] widely used
cholesterol-lowering drugs. In severe cases, statin-associated damage may even lead to
rhabdomyolysis. In fact, statins, by acting as selective inhibitors of HMG-CoA reductase,
an enzyme that catalyzes an early step of the mevalonate pathway, lower both cholesterol
and CoQ biosynthesis. The molecular mechanisms underlying statin-induced myotoxicity
are not well established. Several studies propose that statins promote cell death, inducing
mitochondrial dysfunction. Another hypothesis suggests that myotoxicity is mediated by
inhibition of mitochondrial respiratory chain as a consequence of CoQ depletion. Animal
model studies have been used to support a protective effect of CoQ in association with
statin treatment. In particular, an ex vivo rat study showed that 1 h co-incubation of muscle
fibers obtained from soleus biopsies with increasing concentrations of simvastatin (1-40 µM)
and 1 mM L-carnitine, 100 µM mevalonate or 10 µM CoQ, prevented statin toxicity, support-
ing mitochondrial respiration and protecting against hydrogen peroxide generation [89].
Accordingly, in humans, Wang LW et al. [90] reported that CoQ facilitated the recovery
of patients affected by statin-induced skeletal muscle damage associated with pain and
weakness. In a human double-blind, randomized, placebo-controlled study involving
patients with previous intolerance to statins, 3 months of 100 mg/day of ubiquinone, in
addition to statin (half dose compared to the prescribed dose at enrollment), improves
the perception of clinical symptoms such as asthenia, myalgia or pain [91]. Some authors
hypothesized that muscular mitochondrial dysfunction due to CoQ deficiency induced
by statin treatment might influence also physical performance. In fact, some authors have
observed that CoQ administration (PureSorb-Q40-CoQ10, a water-soluble form of CoQ;
10 mg/L in drinking water) in atorvastatin-treated mice, reversed atorvastatin-related
mitochondrial dysfunction, counteracting statin-induced decrease in oxygen utilization,
improving exercise endurance and tolerance [92]. Within exercise under physiological
condition, only a limited set of studies have investigated the role of CoQ as an antioxidant
supplement in sports nutrition to counteract oxidative stress induced by strenuous exercise.
In fact, despite the beneficial effects of moderate and regular physical exercise, strenuous
exercise, defined as any activity that expends six metabolic equivalents (METS) per minute
or more [93], may become detrimental. In particular, Simon H.B.’s review [94] under-
scores how repetitive intense exercise may have deleterious cardiovascular effects, causing
structural damage to muscle cells, leading to muscle soreness, swelling, prolonged loss
of muscle function, increased ROS production, induction of pro-inflammatory signaling,
impairment of immune functions and leakage of muscle proteins into circulation [95,96].
In these overtraining conditions, subjected to individual training capacity and fitness level,
CoQ supplementation as a mitochondrial nutrient, and in particular ubiquinol, due to its
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antioxidant activity, may modulate these harmful responses. Indeed, due to its antioxidant
function, in addition to its bioenergetic role inside the mitochondria, CoQ has been tested
as an anti-fatigue and ergogenic supplement in relation to physiological challenges, promot-
ing exercise performance and supporting metabolism beyond fatigue threshold. However,
these effects are highly debated, and the available results are controversial. In animal
models it has been shown that ubiquinol supplementation dose-dependently (102.5 mg/kg,
205 mg/kg or 615 mg/kg of body weight) after 28 days reduced serum lactate and creatin
kinase levels induced by forelimb grip strength and exhaustive swimming tests, increas-
ing free fatty acid (FFA) and muscle glycogen content, as major energy reservoir during
exercise [97]. In humans, 200 mg/day ubiquinol oral supplementation for 2 weeks in
healthy and well-trained firemen was able to modulate inflammatory signaling, expression
of pro-inflammatory molecules by increasing some anti-inflammatory cytokines during
high intensity physical exercise, revealing moreover a possible pro-angiogenic effect [98].
Moreover, in the same study, ubiquinol improved energetic substrate supply and muscle
recovery after strenuous exercise. The presently available scientific data highlight that the
variability of biological responses following CoQ intervention are influenced by different
aspects, including dosage, oxidative status of the supplement, time of supplementation,
training level and type of physical exercise approached by users. In fact, in contrast with
previously discussed beneficial effects, Bloomer RJ et al. [99] showed that 1 month of
supplementation with 300 mg/day of ubiquinol in healthy trained individuals, increased
total and reduced blood CoQ but it was not effective in improving exercise performance
nor in lowering oxidative stress markers, after a repeated 5-cycle sprints test. Accordingly,
Orlando P. et al. [84] confirmed these results, showing that 1 month of 200 mg/day of
ubiquinol supplementation minimized exercise-induced CoQ depletion, enhancing plasma
and cellular antioxidant levels, but this was not able to improve physical performance in-
dexes or markers of muscular damage, after a single bout of intense exercise (40 min run at
85% of maximal heart rate). However, according to Gul I et al. [100], supplementation with
ubiquinone 100 mg/day for 8 weeks partially prevented the increase in lipid peroxidation
after repeated short-term supramaximal exercise in healthy sedentary men, emphasizing
the fact that CoQ supplementation is more efficient when associated with moderate and
regular physical exercise.
5. Other Clinical Aspects
Due to its ubiquitous distribution, its pivotal role in mitochondrial bioenergetics and
its antioxidant role in biological membranes, wider clinical applications of CoQ continue to
attract attention in recent research. As discussed earlier, being cardiovascular health a major
field of application of CoQ, it represents a candidate molecule for treatment of systemic
pathologies that significantly overlap with cardiovascular dysfunction, either as a cause
or a consequence, for instance metabolic diseases and neurodegeneration. Considering
these vital functions, CoQ deficiency represents a critical clinical aspect. CoQ deficiency
can result from either a genetic defect in its biosynthetic pathway, known as primary CoQ
deficiency, or it can occur as a result of diseases not associated with this or from certain
pharmacotherapies, and is known as secondary CoQ deficiency [101,102]. Primary CoQ
deficiency is an autosomal recessive condition, and to date, mutations in 10 genes have
been associated with this condition: PDSS1, PDSS2, COQ2, COQ4, COQ5, COQ6, COQ7,
COQ8A, COQ8B, and COQ9 [103]. The clinical presentation of primary CoQ deficiency is
extremely heterogeneous and although there has been some attempt to divide it up into five
distinct clinical phenotypes: encephalomyopathy, severe infantile multisystemic disease,
steroid resistant nephrotic syndrome, cerebellar ataxia and isolated myopathy, other clinical
presentations have also been associated with CoQ deficiency [101,104]. At present, the
incidence of primary CoQ deficiency is estimated to be below 1:100,000, although no precise
epidemiologic data are available, and this condition is thought to be underdiagnosed since
the assessment of endogenous CoQ status is only available at specialist clinical centers [104].
In contrast to primary CoQ deficiencies, the incidence of secondary CoQ deficiencies is
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thought to be relatively common and most recently has been associated with disorders,
such as phenylketonuria (PKU) and the lysosomal storage disorder, mucopolysaccharido-
sis Type III [105]. The actual mechanisms responsible for secondary CoQ deficiencies in
disease is uncertain, although oxidative stress induced catabolism of CoQ together with
the inhibition of the enzymes involved in its synthesis have been suggested [102,106]. As
discussed in the muscle health section, HMG-CoA reductase inhibitors (statins) have been
associated with CoQ deficiency and this has been suggested as a possible contributing
factor to the myopathic side effects associated with this pharmacotherapy [107]. Once
biochemical evidence of a CoQ deficiency has been detected, further studies are required to
determine whether it is a primary or secondary CoQ deficiency [107]. The former determi-
nation requires next generation sequencing diagnostic strategies and the latter may require
radiolabelled incorporation studies [107]. Once diagnosed, patients with CoQ deficiency
respond well to high dose oral CoQ supplementation, although early diagnosis and treat-
ment is essential to ensure an optimal clinical response [104]. Whilst CoQ supplementation
appears to improve peripheral abnormalities, neurological symptoms appear to be more re-
fractory to treatment and this may reflect the limited ability of CoQ to cross the blood–brain
barrier [108]. A deficit in CoQ status has been reported in neurological disorders, resulting
in antioxidant status disturbances and mitochondrial dysfunction frequently leading to
severe neuronal degeneration [109,110]. Therefore, CoQ supplementation has been exten-
sively used as a treatment in neurodegenerative diseases, including Alzheimer’s disease
(AD), Parkinson’s disease (PD) and Multiple Sclerosis (MS) where it has been shown to
exert neuroprotective effects against oxidative stress-induced damage and mitochondrial
respiratory chain (MRC) dysfunction. Experimental studies have suggested CoQ as a po-
tential therapeutic candidate, preventing the harmful effects of β-amyloid (Aβ) deposition
on human endothelial cells in early asymptomatic stages of AD, therefore, delaying the pro-
gression of severe neuropathology [111]. Pre-treatment with CoQ prevented Aβ-induced
cellular toxicity and oxidative injury by inhibiting Aβ trafficking and accumulation into
the mitochondria, cytochrome c release and mitochondrial permeability transition pore
(mPTP) opening, and superoxide anion (O2•-) and hydrogen peroxide (H2O2) production.
The presence of Aβ significantly elevates serum MDA and total oxidant levels, in addition
to a reduction in antioxidant enzyme activity, including SOD, GPx and CAT, resulting
in impaired synaptic plasticity in a rat model of AD [112]. CoQ supplementation was
found to significantly reverse these consequences, suggesting that treatment with CoQ
can prevent the harmful effects of Aβ on hippocampal synaptic plasticity via increasing
the total antioxidant capacity (TAC) levels. Alzheimer type dementia is a characteristic
feature of Down Syndrome (DS) patients associated with increased oxidative stress and
premature senescence. A lower plasma content of CoQ was observed in young patients
with DS compared to healthy subjects of the same age and is positively correlated with
the intelligence quotient, suggesting a role of this molecule in neurodevelopment [113].
CoQ intervention in DS children was conducted within a 5-year intervention trial and,
despite previous promising results [2], supplementation with 4 mg/kg per day of CoQ in
the oxidized form led to no effects on DNA oxidation at both short (6 months) [114] and
long-term treatment (4 years) [115]. Nonetheless, as pointed out by the authors, both the
therapeutic dosage and the form of CoQ used were not ideal for this intervention. In fact,
Miles et al., 2007 [116] have shown that 10 mg/kg of ubiquinol was able to significantly
improve oxidative imbalance in DS patients. In other neurodegenerative disorders, such as
PD, reduced plasma levels of total CoQ and elevated ratios of oxidized CoQ/total CoQ
have been reported, suggesting that CoQ oxidation may have a pathogenic role in PD [117].
In a PD rat model, the intrastriatal distribution of CoQ was demonstrated to inhibit apop-
tosis, resulting in an elevation of factors responsible for neuronal growth and enhanced
angiogenesis, suppressing neurodegeneration and preventing the progression of PD [118].
In MS, CoQ-treated patients (500 mg/day) were found to have significant elevations in
SOD activity and plasma total antioxidant capacity (TAC) and reductions in MDA levels
in comparison to the placebo control group, suggesting that CoQ can increase the activity
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of antioxidant enzymes and reduce oxidative stress in patients with MS [119]. However,
patients with a CoQ deficiency often show inconsistent responses to oral CoQ supplementa-
tion, with neurological disease patients demonstrating the highest percentage of ineffective
results [108,120]. Poor uptake of CoQ treatment in neurodegenerative disease may be due
to its low oral bioavailability, poor solubility and transfer across the blood–brain barrier,
which may compromise its effectiveness as a treatment for neurodegenerative disorders.
The development of CoQ-loaded nanoemulsions have been studied in order to improve
the oral bioavailability of CoQ supplementation in rat models of PD, which was shown
to reduce nigrostriatal dopamine depletion, significantly improving behavioral activity
in comparison to control rats treated with a CoQ suspension [121]. In addition, reduced
elevated levels of thiobarbituric acid reactive substances (TBARs) and increased glutathione
levels were reported. In a mouse model of mitochondrial encephalopathy (Coq9X/X),
oral ubiquinol-10 supplementation—a water-soluble, reduced form of CoQ—was found
to increase CoQ concentrations in the cerebrum of Coq9X/X mice, demonstrating that
ubiquinol-10 may be more effective at increasing CoQ-dependent MRC complex activi-
ties as well as reducing cerebral oxidative damage, therefore improving the efficacy of
CoQ therapy in neurodegenerative diseases [120]. Therefore, these findings suggest that
CoQ adjuvant treatments can enhance the bioavailability and antioxidant properties of
CoQ, therefore providing a promising treatment for neurodegenerative disorders. An-
other important field of application is represented by diabetes, and its cardiovascular and
neuropathic complications. Diabetic neuropathy is the main complication of diabetes.
The long-term administration of CoQ in diabetic rat [122] and mouse [123,124] models
decreases oxidative stress and lipid peroxidation, increasing TAC and glutathione (GSH)
levels, modulates the expression of caspase 3 and UCP2 proteins, and reduces proinflam-
matory factors, resulting in a reduction in atrophy and loss of dorsal root ganglion (DRG)
neurons, as well as improvement of motor function and neuropathic pain-downregulating
phospholipase C β3. These effects are potentiated by CoQ and alpha-lipoic acid (ALA)
co-treatment [122]. CoQ administration inhibits other diabetic complications such as
glomerulosclerosis and leukocyte infiltration [125]. This could be due to the protection
of endothelial cells from apoptosis and dysfunction induced by high glucose through the
AMPK pathway [126]. In murine glomerular endothelial cells (mGECs), CoQ protected
against diabetic nephropathy-induced mitochondrial dysfunction via mitophagy by restor-
ing Nrf2/ARE signaling [127]. Moreover, in murine cross-generational models of insulin
resistance in the offspring, associated with poor maternal nutrition, post-weaning CoQ
supplementation has been shown to have anti-inflammatory properties and to modulate
insulin-signaling protein expression, thus preventing the development of insulin resistance
associated with rapid post-natal growth [128]. Finally, CoQ intervention has also been
tested in relation to nephrological and hepatological dysfunction. In this respect, there are
conflicting data on the effects of CoQ in kidney disease. In a gentamycin-induced nephro-
toxicity rat model, CoQ effect was mild and limited to a lower rate of tubular necrosis and
hyalen accumulation [129]. On the contrary, in patients with lithiasis undergoing extracor-
poreal shockwave lithotripsy, CoQ improved renal injury increasing glomerular filtration
and decreasing albumin/creatinine ratio and β2-microglobulin level, in addition to the
improvement in vasoactive molecules (renin and aldosterone) and in pro-inflammatory
mediator levels. However, these changes were not associated with enhancement in oxida-
tive stress parameters [130]. In haemodialysis patients, CoQ plasma level was positively
correlated with brachial artery flow-mediated dilatation and negatively correlated with
oxidative markers (MDA and 8-hydroxydeoxyguanosine) suggesting that low CoQ levels
could contribute to endothelial dysfunction in these patients [131]. Finally, CoQ through
its antioxidant and anti-inflammatory properties, was found to have positive effects on
biochemical parameters related to various pathologies, such as non-alcoholic fatty liver
disease (NAFLD) [132], and to protect against the side effects of anticancer therapy, such
as radiotherapy-induced gastrointestinal injury in patients with pelvic tumors [133] and
doxorubicin (DOX)-induced testicular toxicity [134].
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6. Emerging Applications of Coenzyme Q10
Two emerging areas of investigation of CoQ in health in the last decade refer to
ophthalmological interventions and skin ageing research.
Retinal disease, such as age-related macular degeneration, diabetic retinopathy, re-
tinitis pigmentosa and glaucoma, are the major causes of blindness in the world and are
characterized by oxidative stress. In the retina, high oxygen consumption results in the
production of large amounts of ROS that could promote cellular damage and, subsequently,
retinal degeneration. Due to its antioxidant properties, CoQ topical eye preparations have
demonstrated potential beneficial effects for patients with retinal disease. In particular,
CoQ has been reported to have beneficial effects on glaucoma, a multifactorial neurode-
generative disorder during which oxidative stress activates astrocytes that are involved
in optic nerve head (ONH) remodeling, associated with the pathogenesis of glaucoma. In
rat ONH astrocytes exposed to H2O2, CoQ treatment prevented cell activation, decreasing
SOD2 and hemeoxygenase-1 (HO–1) protein expression, and loss of mitochondrial mass.
In addition, CoQ counteracted the decrease in cell viability and ATP and the increment
in ROS production [135]. Similar results in improving retinal ganglion cell degeneration
by preventing oxidative stress, mitochondrial alterations and astroglial activation were
observed in glaucomatous DBA/2J mice fed with CoQ (1% v/v) for 6 months [136]. While
open-angle glaucoma (OAG) patients treated with eye drops containing CoQ and vitamin
E (in addition to a β-blocker monotherapy) for 12 months showed beneficial effects on
functions of the inner retina and enhanced visual cortical response [137]. Moreover, the
combination of two antioxidants, CoQ and melatonin, and an anti-inflammatory drug,
dexamethasone, incorporated in a novel multi-loaded poly lactic-co-glycolic acid (PLGA)-
microspheres, has been proposed as a novel neuroprotective intraocular therapy for the
treatment of glaucoma [138]. CoQ in ophthalmic solution has also been shown to reduce
corneal damage associated with UVB exposure in both in vitro and in vivo models. In
UVB-exposed human corneal cells, CoQ supplementation led to an increased survival rate
and mitochondrial function counteracting ATP decline. In a rabbit model, treatment with
CoQ eye drops (2 per eye every 8 h for 3 days) reduced UVB-induced vessel hyperemia
and promoted corneal wound healing after corneal epithelium removal [139]. CoQ, due to
its antioxidant properties, protected ganglion cell death in mouse ischemic retina, decreas-
ing oxidative stress and counteracting the increased expression of apoptosis-associated
protein Bax and activation of both astroglial and microglial cells, thus decreasing the ex-
pression of glial fibrillary acidic protein and ionized calcium-binding adapter molecule 1
(Iba-1) [140]. In humans, CoQ oral supplementation (100 mg per day), in combination with
vitamins, has also been shown to improve the visual field in retinal dysfunction caused by
vascular disorders, such as non-arteritic ischemic optic neuropathy, retinal artery occlusion and
hemianopia/quadrantanopia [141]. In conclusion, CoQ has demonstrated protective effects on
different retinal diseases by decreasing oxidative stress, counteracting microglia cell activation
and maintaining mitochondrial functionality, thus resulting a key molecule in eye health.
Skin is the largest organ of the body which directly interfaces with the external environ-
ment, and it is therefore constantly challenged by environmental factors, such as ultraviolet
(UV) radiation, smoking and pollution, all of which contribute to extrinsic aging of skin, in
contrast to intrinsic aging due to genetic factors [142]. In the skin, CoQ is found in both
cells of the human dermis and epidermis where, in the latter, its concentration is 10-fold
higher [143] and where approximately 46% of total CoQ is present in its reduced form [144].
It is also a constituent of skin surface lipids (SSL) of the stratum corneum (SC). Previous
studies prior to 2010 have shown that CoQ levels in skin and SSL decline with age and with
UV exposure [145–147] and this has been supported by more recent advancements in the
understanding of the role of CoQ in skin aging. Marcheggiani et al. [148] demonstrated, in
cultured human dermal fibroblasts (HDF), that the depletion of CoQ is not a consequence
but a cause of skin aging. Furthermore, in the same study, supplementation with ubiquinol
led to increased bioavailability, compared to its oxidized form in a senescence model of skin
ageing, and was shown to be more efficient in rescuing the senescent phenotype both at the
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cellular and mitochondrial levels [149]. These results appear to reinforce the role that CoQ
has in minimizing skin aging and are in line with the work from Zmitek et al. conducted
on human volunteers to demonstrate the important role that dietary intake of CoQ has
on improving skin structural features associated with skin aging (mimic wrinkles/poor
skin tone/visual dryness). On a cohort of 34 healthy female volunteers aged between
45–65 years, those receiving an investigational product for 12 weeks, based on a liquid food
supplement, characterized by a combination of water-soluble CoQ (Q10Vital®, 50 mg) and
fish collagen (4.0 g), reported better skin parameters compared to placebo controls [150].
However, no significant effects of the supplementation on skin hydration, dermis thickness,
transepidermal water loss (TEWL) and viscoelasticity were observed. This was in accor-
dance with a previous study on a cohort of 33 female volunteers [151] where in those given
the same liquid food supplement but containing only CoQ (either 50 or 150 mg/day for
12 weeks), a significant reduction in periorbital wrinkles, microrelief lines, and improved
skin smoothness with both doses was seen, whereas the higher dose led to additional
improvement of wrinkles in other facial parts. Further beneficial effects of CoQ on skin
aging have also surfaced with the advent of new technologies, such as the Seahorse XF24
extracellular flux analyzer. With this method, Schniertshauer et al. demonstrated that
mitochondrial respiration and ATP production in epithelial tissue derived from human
skin biopsies (male and female donors, 29–84 years, undergoing general or plastic surgery)
decreased with donor age (approximately 10%/decade). Respiratory parameters were
restored when the reduced form of CoQ, ubiquinol, was administered as a formulation
(QuinoMit Q10 fluid, 100 µM) to the overnight-separation media. The authors concluded
that these effects were mainly caused by an increase in the electron transport chain [152].
Indeed, exogenously added CoQ appears to act as an “electron clamp” enhancing electron
transport between complexes I/II and III in the mitochondrial respiratory chain, which
becomes “leaky” over the years. This study confirmed earlier work by Knott et al., where
the seahorse system showed that treatment with 18 µM ubiquinone, a quantity comparable
to that found within the human epidermis after 2 weeks of topical application of a test
formula containing 870 µM ubiquinone, significantly stimulated energy metabolism in
human cultured keratinocytes. Furthermore, these same authors showed that the applica-
tion of ubiquinone on 73 healthy, non-smoking, female volunteers (20–66 years) led to a
significant increase in ubiquinol in human epidermis, thus indicating effective supplemen-
tation and transformation. Additionally, they demonstrated that topical CoQ was capable
of improving the antioxidant properties of stressed skin [153]. Obviously, effective topical
delivery depends on the delivery system used, and several studies in recent years have
investigated this aspect, especially with regard to CoQ delivered by nano-structured lipid
carriers (NLC), innovative carrier systems derived from oil/water (o/w) emulsions. Indeed,
the first NLC-containing cream on the cosmetic market was introduced in 2005 and it con-
tained ubiquinone, the Cutanova Nanorepair Q10 cream (Dr. Rimpler GmbH, Wedemark,
Germany). Pardeike et al. [143] investigated this cream containing 0.48% ubiquinone with
an identical o/w emulsion containing no NLC but the same concentration of ubiquinone.
They observed on a cohort of 50 volunteers (22–57 years), that skin hydration and sub-
jective feeling was significantly higher with the Nanorepair Q10 cream. Yue et al. [154]
showed that CoQ incorporated in NLC, based on soybean lecithin, efficiently protected
HDF against UVA-induced oxidative damage and restored SOD and glutathione peroxidase
activities compared to a CoQ emulsion. Furthermore, the skin penetration capability of
CoQ-NLC versus CoQ-emulsion was greater. This study enforces the role that NLC-based
formulations could have an ineffective topical drug delivery of CoQ. Bruge et al. [155]
later compared the efficacy of NLC loaded with either the oxidized or the reduced forms
of CoQ against UVA-mediated damage in HDF and found that only reduced CoQ-NLC
was efficient in counteracting UVA-associated mitochondrial depolarization, suggesting a
potential role of this molecule in anti-aging cosmetic formulations. Nanoemulsions (NE)
have also been explored to optimize topical skin permeability of CoQ. El-Leithy et al. [156]
tested the solubility of CoQ in various oils, surfactants, and co-surfactants and came up
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with an optimized formula consisting of 10% w/w isopropyl myristate (oil phase), 60% w/w
Tween 80:Transcutol HP mixture at a ratio 2:1, 30% w/w water and 2% w/w ubiquinone.
When tested on the dorsal skin of 12–18-month-old female rats, applied twice daily for
1 month, a reduction in skin wrinkles and smoother skin compared to the control emulsion
devoid of CoQ was observed. Besides CoQ’s role as an antioxidant and energizer in skin,
recent studies point to its possible role as anti-inflammatory and skin-whitening agent.
Zhang et al. [157] observed that CoQ (0.5–2 µM) dose-dependently reduced melanin syn-
thesis by inhibiting tyrosinase activity in melanoma B16 cells, which points to the potential
depigmentation effect of CoQ in skincare products. It also decreased IL-1α expression in
UVB-irradiated HaCaTs, suggesting an anti-inflammatory function of CoQ. Furthermore,
CoQ dose-dependently (0.5–10 µM) enhanced elastin and collagen IV gene expression, as
well as cell proliferation in adult fibroblasts, and inhibited ROS production and MMP-1
content in both UVA/B-irradiated fibroblasts and HaCaTs.
7. Concluding Remarks
In the second decade of the new millennium, 64 years after its discovery, CoQ research is
still attracting a lot of interest in the scientific community, both in relation to its multifaceted
mechanism of action and for its wide range of applications in human health (Figure 1). In
terms of research article production, reviewed here, the major areas of intervention remain
cardiovascular health and human fertility. In these studies, the beneficial effects of CoQ mainly
rely on its well-known bioenergetic and antioxidant functions, although novel interactions
with cellular biochemical pathways through redox signaling and modulation of mitochondrial
function are progressively being described. Limited bioavailability of CoQ remains a major
issue for its use, although novel formulation strategies and the direct use of ubiquinol, which
does not require cellular reduction and is more available to cellular compartments, are highly
investigated. In this respect, topical application where the reduced form is particularly advan-
tageous over conventional ubiquinone, represents an emerging area of interest, encompassing
both dermatological and ophthalmological applications.
Figure 1. Areas of CoQ10 application in human studies for improving human health. CNS = Central
Nervous System.
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Table 1. Clinical evidence on the impact of CoQ supplementation on cardiovascular disease-related outcomes.
Author, Year Country Participants CoQ10 Dosage and Duration Main Findings
[158] Kurban et al.,
2010 Turkey Healthy volunteers
Received 100 or 150 mg/day
acetylsalicylic acid for 2
months before quantification
of total CoQ10











Received 300 mg/day CoQ10
(ubiquinone) for 8 weeks
Improved mitochondrial
function and flow-mediated
dilation (FMD) to enhance
endothelial function
[159] Fumagalli





Received 320 mg/day of
Q-terclatrate (equivalent to 16
mg of native CoQ10) and 340
mg/day of creatine for 8 weeks
Improved exercise tolerance,
by enhancing peak oxygen
consumption and quality of
life



















Quantification of total plasma
CoQ10 (ubiquinol) levels
Atorvastatin and rosuvastatin,
when combined with exercise
could significantly preserve
ubiquinol levels associated
with an increase in HDL-c








Quantification of total plasma
CoQ10 levels
Low CoQ10 levels are
associated with increased
arterial stiffness
[163] Brugè et al.,
2012 Italy Healthy subjects
Received 20 mL extra virgin
olive oil per day for 2 weeks,
followed by 2 weeks of olive
oil enriched with 20 mg and 2
more weeks with 40 mg of
CoQ10 (ubiquinol)
Increased plasma levels of
CoQ10 were associated with
reduced susceptibility of LDL
to peroxidation and improved
redox status
[164] Larijani et al.,
2013 United States Firefighters
Received 300 mg/tablet aged




beneficial effects on vascular
elasticity and endothelial
function




Quantification of total plasma
CoQ10 levels
Higher CoQ10 concentration
was correlated with a lower
risk of CAD, even after
adjusting for the risk factors
for CAD
[48] Lee et al., 2012 Taiwan Patients with CAD
Received 60 or 150 mg/day of
CoQ10 (ubiquinone) for 12
weeks
Higher CoQ10 dose (150 mg)
reduced oxidative stress
parameters like lipid
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Table 1. Cont.
Author, Year Country Participants CoQ10 Dosage and Duration Main Findings
[56] Perez-Sanchez











the expression of tissue factor,
VEGF, and Flt1




Received 150 mg twice a day
or a single dose 300 mg/day
CoQ10 (ubiquinone) for 12
weeks










Received 100 mg/3 times a day
to total 300 mg/day of CoQ10






(BNP), and long-term Outcome
(hospitalizations/mortality)





Received 100 mg/3 times a day
to total 300 mg/day of CoQ10
(ubiquinol) for 12 weeks
High plasma CoQ10 levels








glutathione levels were not
affected




Received 200 mg/day CoQ10
(ubiquinone) plus 200 µg/day
organic selenium for 48
months to a 10-year follow-up
Significantly reduced
cardiovascular mortality,
confirmed not at intervention
but during 10-year follow-up






Received 200 mg/day CoQ10
(ubiquinone) for 12 weeks
Although did not affect total












Received 100 mg/day CoQ10
(ubiquinone) for 12 weeks
Beneficial effects of CoQ10
were related to decreasing
some pro-inflammatory
factors, such as IL-6 and
high-sensitivity C-reactive
protein (hs-CRP), and in
increasing adiponectin
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Table 1. Cont.
Author, Year Country Participants CoQ10 Dosage and Duration Main Findings
[166] Pérez-Sánchez




Received 200 mg/day CoQ10









peroxides and percentage of
monocytes with depolarized
mitochondria





Received 300 mg/day CoQ10













Received 400 mg/day CoQ10








Received 100 or 200 mg/day




was in part by improving
blood flow through enhancing
nitric oxide bioavailability and
lowering oxidized low-density
lipoprotein cholesterol






amlodipine and ethoxidol on
the endogenous CoQ10 plasma
concentration
Patients with CVDs treated
with various drugs had CoQ10
plasma level statistically
significantly lower than in
practically healthy individuals




Received 30 mg/day of CoQ10
(ubiquinone) for 6 and 12
months
CoQ10 induced significant
reduction in the level of
malondialdehyde and may
attenuate the incidence of atrial
fibrillation in patients with HF




Received 400 mg/day of
CoQ10 (ubiquinol) from 7 days
before to 5 days after surgery
Post-operative increase in
troponin I was curbed, plasma
CoQ10 declined and oxidation
were counteracted




Received 200 mg/day of
ubiquinone for 4 weeks before
and 200 mg/day of ubiquinol
for other 4 weeks, after 4
weeks of washout
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